Literature DB >> 20425524

Dermatomyositis and type 1 interferons.

Steven A Greenberg1.   

Abstract

Dermatomyositis is a poorly understood multisystem disease predominantly affecting skin and muscle. This review focuses on the potential role of a group of related cytokines, the type 1 interferons, in the pathogenesis of dermatomyositis. Type 1 interferon-inducible transcripts and proteins are uniquely elevated in dermatomyositis muscle compared with all other muscle diseases studied to date. The endothelial cell tubuloreticular inclusions present in affected dermatomyositis muscle are biomarkers of type 1 interferon exposure. The cell-poor lichenoid reaction in skin with predominant involvement of the basal epidermal cell layer and its topologic equivalent in muscle, perifascicular atrophy, may be lesions that develop directly in response to type 1 interferon signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425524      PMCID: PMC2929916          DOI: 10.1007/s11926-010-0101-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  39 in total

1.  History of dermatomyositis.

Authors:  Todd D Levine
Journal:  Arch Neurol       Date:  2003-05

2.  Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels.

Authors:  B Q Banker
Journal:  J Neuropathol Exp Neurol       Date:  1975-01       Impact factor: 3.685

3.  The childhood type of dermatomyositis.

Authors:  S Carpenter; G Karpati; S Rothman; G Watters
Journal:  Neurology       Date:  1976-10       Impact factor: 9.910

4.  Endothelial inclusions in dermatomyositis.

Authors:  W L Norton; E Velayos; L Robison
Journal:  Ann Rheum Dis       Date:  1970-01       Impact factor: 19.103

5.  Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions.

Authors:  S A Rich; T R Owens; L E Bartholomew; J U Gutterman
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon.

Authors:  P M Grimley; G L Davis; Y H Kang; J S Dooley; J Strohmaier; J H Hoofnagle
Journal:  Lab Invest       Date:  1985-06       Impact factor: 5.662

Review 7.  A gene expression approach to study perturbed pathways in myositis.

Authors:  Steven A Greenberg
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

Review 8.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 9.  Uncertainties in the pathogenesis of adult dermatomyositis.

Authors:  Steven A Greenberg; Anthony A Amato
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

Review 10.  Type 1 interferons and myositis.

Authors:  Steven A Greenberg
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

View more
  31 in total

Review 1.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

2.  Novel approaches in the treatment of myositis and myopathies.

Authors:  Jemima Albayda; Lisa Christopher-Stine
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

Review 3.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

Review 4.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 5.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

6.  Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis.

Authors:  T Fujiyama; T Ito; N Ogawa; T Suda; Y Tokura; H Hashizume
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 7.  [Dermatomyositis-update].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 8.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 9.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 10.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.